UNRESECTABLE PANCREATIC CARCINOMA
Clinical trials for UNRESECTABLE PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo targets Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-stage trial tests whether adding the drug bosentan to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with pancreatic cancer that cannot be removed by surgery. The study involves 21 adults and aims to find the best dose of bosent…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of drugs and radiation targets tough pancreatic tumors
Disease control TerminatedThis early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already rec…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Virus-Immunotherapy cocktail takes on tough GI cancers
Disease control OngoingThis early-stage trial is testing a combination of pelareorep (a reovirus) and atezolizumab (an immunotherapy) along with standard chemotherapies in people with advanced anal or pancreatic cancers. The study aims to find safe doses, look for biomarkers that predict response, and …
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a diabetes drug and special diet boost chemo for pancreatic cancer?
Disease control OngoingThis early-phase trial is testing whether adding the diabetes drug metformin and a specific dietary supplement (including curcumin, vitamins, and other natural compounds) to standard chemotherapy (gemcitabine and abraxane) is safe and feasible for people with pancreatic cancer th…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC